Mario Campone

52.5k total citations · 11 hit papers
538 papers, 23.9k citations indexed

About

Mario Campone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mario Campone has authored 538 papers receiving a total of 23.9k indexed citations (citations by other indexed papers that have themselves been cited), including 379 papers in Oncology, 266 papers in Pulmonary and Respiratory Medicine and 155 papers in Cancer Research. Recurrent topics in Mario Campone's work include Advanced Breast Cancer Therapies (190 papers), Cancer Treatment and Pharmacology (190 papers) and HER2/EGFR in Cancer Research (155 papers). Mario Campone is often cited by papers focused on Advanced Breast Cancer Therapies (190 papers), Cancer Treatment and Pharmacology (190 papers) and HER2/EGFR in Cancer Research (155 papers). Mario Campone collaborates with scholars based in France, United States and Spain. Mario Campone's co-authors include Bella Kaufman, Jean-Marc Ferrero, José Baselga, Hope S. Rugo, Fabrice André, Eva Ciruelos, Javier Cortés, L. Campion, David Cameron and Andreas Schneeweiß and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Mario Campone

514 papers receiving 23.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 2.5k citations Bella Kaufman, Mario Campone et al. New England Journal of Medicine profile →
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019 1.6k citations Fabrice André, Eva Ciruelos et al. New England Journal of Medicine profile →
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

2015 1.4k citations José Baselga, Mario Campone et al. New England Journal of Medicine profile →
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Mario Campone, Angelo Di Leo et al. Journal of Clinical Oncology profile →
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

2013 700 citations Mario Campone, José Baselga et al. profile →
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

2012 522 citations Thomas Bachelot, Mario Campone et al. profile →
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

2009 504 citations José Baselga, Mario Campone et al. Journal of Clinical Oncology profile →
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. profile →
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Shinzaburo Noguchi, Kathleen I. Pritchard et al. profile →
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

2020 371 citations Fabrice André, Dejan Juric et al. profile →
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

2017 337 citations Sara A. Hurvitz, Mario Campone et al. profile →

Peers

Countries citing papers authored by Mario Campone

Since Specialization

Citations

This map shows the geographic impact of Mario Campone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Campone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Campone more than expected).

Fields of papers citing papers by Mario Campone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Campone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Campone. The network helps show where Mario Campone may publish in the future.

Co-authorship network of co-authors of Mario Campone

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Campone. A scholar is included among the top collaborators of Mario Campone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Campone. Mario Campone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Leveraging selection for function in tumor evolution: System-level cancer therapies 2025 ·Evolution Medicine and Public Health ·Frédéric Thomas, Jean‐Pascal Capp, Antoine M. Dujon, Andriy Marusyk, (unknown), Mario Campone, Pascal Pujol, (unknown), (unknown), Beáta Újvári, Robert A. Gatenby, Aurora M. Nedelcu	1
2	MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblasts 2025 ·Cell Death and Disease ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David Chiron, François Guillonneau, Lucas Treps, Mario Campone, Philippe Juin, Frédérique Souazé	1
3	Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up 2024 ·The Breast ·(unknown), S. Mirallié, (unknown), (unknown), Pierre‐Emmanuel Bouet, (unknown), (unknown), (unknown), M-A Mouret-Reynier, (unknown), (unknown), (unknown), M Robert, Thomas Fréour, Mario Campone, Audrey Blanc-Lapierre, (unknown)	2
4	Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292 2024 ·Cancer Research ·Erika Hamilton, Patrick Neven, Barbara Pistilli, Muralidhar Beeram, Virginia F. Borges, Mario Campone, José Luiz Guimarães, Theodoros Foukakis, Annette Raskov Kodahl, Peter Lau, Elgene Lim, Iwona Ługowska, (unknown), Christopher Gresty, Claire Miller, Roberto Sommavilla, Dhivya R. Sudhan, Hope S. Rugo	2
5	Abstract PS02-01: Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials 2024 ·Cancer Research ·Lowell L. Hart, Seock‐Ah Im, Sara M. Tolaney, Mario Campone, Timothy Pluard, Berta Sousa, Gilles Freyer, (unknown), Kevin Kalinsky, (unknown), Melissa Gao, Huilin Hu, Sherko Küemmel	1
6	Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial 2023 ·Clinical Cancer Research ·Tobias Keßler, Daniel Schrimpf, (unknown), (unknown), Leon D. Kaulen, (unknown), Martin J. van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaïh, Julien Dômont, Paul M. Clément, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick	11
7	COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19) 2023 ·Cancers ·Valérie Seegers, Guillaume Rousseau, Ke Zhou, Audrey Blanc-Lapierre, Frédéric Bigot, Hakim Mahammedi, Aurélien Lambert, (unknown), Mario Campone, Thierry Conroy, Frédérique Penault‐Llorca, M. Bellanger, Jean‐Luc Raoul	2
8	Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy 2022 ·Cancer Research Communications ·Agnès Basseville, (unknown), (unknown), Wilfried Gouraud, Hamza Lasla, Fabien Panloup, Mario Campone, Pascal Jézéquel	2
9	Automatic Segmentation of Metastatic Breast Cancer Lesions on 18F-FDG PET/CT Longitudinal Acquisitions for Treatment Response Assessment 2021 ·Cancers ·(unknown), Caroline Rousseau, (unknown), (unknown), (unknown), Ludovic Ferrer, M. Lacombe, (unknown), (unknown), Pascal Jézéquel, Mario Campone, Nicolas Normand, Mathieu Rubeaux	18
10	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer breakdown → 2019 ·New England Journal of Medicine ·Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, Pierfranco Conté, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, (unknown), David Mills, Celine Wilke, Samit Hirawat, Dejan Juric	1565
11	Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer 2018 ·Expert Opinion on Drug Metabolism & Toxicology ·Marie Robert, Jean‐Sébastien Frenel, Emmanuelle Bourbouloux, (unknown), Anne Patsouris, Paule Augereau, (unknown), Mario Campone	8
12	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2. 2017 ·Journal of Clinical Oncology ·Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Stephanie Manson, Santosh Sutradhar, (unknown), Wolfgang Janni	9
13	Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014) 2017 ·Open Repository and Bibliography (University of Liège) ·Shrushma Loi, Anita Giobbie‐Hurder, Andrea Gombos, (unknown), Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, (unknown), Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, G. Viale, MM Regan, Fabrice André	5
14	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations 2016 ·Cancer Research ·Yu Fu, Cécile Jovelet, Thomas Filleron, Marion Pedrero, Nelly Motté, Yannick Boursin, (unknown), Christophe Massard, Mario Campone, Christelle Lévy, Véronique Dièras, Thomas Bachelot, Julie Garrabey, Jean‐Charles Soria, Ludovic Lacroix, Fabrice André, Céline Lefèbvre	11
15	A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer. 2015 ·Journal of Clinical Oncology ·Ingrid A. Mayer, Christian F. Singer, Peter A. Fasching, Frankie A. Holmes, Michael Gnant, Laura García‐Estévez, Mario Campone, Michael Hubalek, Antonio C. Wolff, José Alejandro Pérez Fidalgo, Eric P. Winer, (unknown), (unknown), Lars Blumenstein, Nathalie Fretault, Iván Díaz-Padilla, Carlos L. Arteaga	1
16	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer 2013 ·Cancer Research ·Marine Malleter, Sébastien Tauzin, Alban Bessede, Rémy Castellano, Armelle Goubard, Florence Godey, Jean Lévêque, Pascal Jézéquel, L. Campion, Mario Campone, Thomas Ducret, Gaëtan MacGrogan, Laure Debure, Yves Collette, Pierre Vacher, Patrick Legembre	69
17	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer 2013 ·Clinical Cancer Research ·Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, José Manuel Pérez-García, Sara A. Hurvitz, Nicholas C. Turner, Hope S. Rugo, John W. Smith, Stéphanie Deudon, Michael Shi, Yong Zhang, Andrea Kay, Diana Graus Porta, A. Yovine, José Baselga	251
18	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 2013 ·JNCI Journal of the National Cancer Institute ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, (unknown), Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard	77
19	Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab 2010 ·Journal of Clinical Oncology ·Fabrice André, Mario Campone, Ruth O’Regan, C. Manlius, Cristian Massacesi, (unknown), Pabak Mukhopadhyay, Jean‐Charles Soria, Michael Naughton, Sara A. Hurvitz	148
20	[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]. 2003 ·PubMed ·Mario Campone, Jean‐Louis Merlin, P. Fumoleau	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact